Treatment of Benzodiazepine Dependence in Methadone Maintenance Treatment Patients: A Comparison of Two Therapeutic Modalities and the Role of Psychiatric Comorbidity

Weizman, Tal; Gelkopf, Marc; Melamed, Yuval; Adelson, Miriam; Bleich, Avi

doi:10.1046/j.1440-1614.2003.01211.x

Cited by 56 publications

(44 citation statements)

References 20 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients who are alcohol or drug dependent may also benefit from this approach. 23 These people are often difficult to manage and should be referred to a specialist addiction service. To support management in rural and remote settings, health professionals in all states and territories have access to 24-hour phone support services.…”

Section: Stabilisation and Maintenance Therapymentioning

confidence: 99%

Management of benzodiazepine misuse and dependence

Brett¹,

Murnion²

2015

Aust Prescr

180

121

View full text Add to dashboard Cite

Section: Stabilisation and Maintenance Therapymentioning

confidence: 99%

Management of benzodiazepine misuse and dependence

Brett¹,

Murnion²

2015

Aust Prescr

180

121

View full text Add to dashboard Cite

“…Patients were then either detoxified from or maintained on clonazepam, and outcome measured was selfreported illicit benzodiazepine use. Illicit benzodiazepine use was reduced in the maintenance group compared with the detoxification group (Weizman et al, 2003) Other small studies in benzodiazepine-dependent methadonemaintained patients have examined community reduction and contingency management. McDuff et al (1993) (III) reported that 12 out of 22 patients misusing primarily alprazolam completed an outpatient reduction procedure which averaged 7.8 weeks.…”

Section: Management Of Benzodiazepine Dependence In High-dose And/or mentioning

confidence: 99%

BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

Welch²,

et al. 2012

View full text Add to dashboard Cite

The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short-and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. KeywordsSubstance misuse, addiction, guidelines, pharmacotherapy, comorbidity 1 Imperial College London, CNWL NHS Foundation Trust, London, UK 2 Gether NHS Foundation Trust, Gloucester, UK 3 Pennine Care NHS Foundation Trust, Ashton-under-Lyne, UKOther invited participants at the consensus meeting who contributed to the discussion and commented on the guidelines were Drummond C, Farrell M, Gilvarry E, Strang J. John, a user representative, read and commented on the written guidelines. Prof W van den Brink reviewed the written guidelines.

show abstract

“…An Australian study (Weizman et al, 2003) compared two therapeutic modalities for BZD dependent patients in MMT: either BZD detoxification or BZD maintenance showing that those maintained on BZD are more successful than those detoxified from BZD. In this study, psychiatric comorbidity was positively related to success of BZD maintenance treatment.…”

Section: Introductionmentioning

confidence: 99%